key: cord-0822169-x2h8nbgv authors: Zein, Ahmad Fariz Malvi Zamzam; Sulistiyana, Catur Setiya; Raffaelo, Wilson Matthew; Pranata, Raymond title: Ivermectin and mortality in patients with COVID-19: A systematic review, meta-analysis, and meta-regression of randomized controlled trials date: 2021-06-27 journal: Diabetes Metab Syndr DOI: 10.1016/j.dsx.2021.102186 sha: 72c91742b6a0044d401084d97eebba828f1adb65 doc_id: 822169 cord_uid: x2h8nbgv AIMS: This systematic review and meta-analysis aims to investigate the effect of ivermectin on mortality in patients with COVID-19. METHODS: A comprehensive systematic literature search was performed using PubMed, Scopus, Embase, and Clinicaltrials.gov from the inception of databases up until April 9, 2021. The intervention group was ivermectin and the control group was standard of care or placebo. The primary outcome was mortality reported as risk ratio (RR). RESULTS: There were 9 RCTs comprising of 1788 patients included in this meta-analysis. Ivermectin was associated with decreased mortality (RR 0.39 [95% 0.20–0.74], p = 0.004; I(2): 58.2%, p = 0.051). Subgroup analysis in patients with severe COVID-19 showed borderline statistical significance towards mortality reduction (RR 0.42 [95% 0.18–1.00], p = 0.052; I(2): 68.3, p = 0.013). The benefit of ivermectin and mortality was reduced by hypertension (RR 1.08 [95% CI 1.03–1.13], p = 0.001); but was not influenced by age (p = 0.657), sex (p = 0.466), diabetes (p = 0.429). Sensitivity analysis using fixed-effect model showed that ivermectin decreased mortality in general (RR 0.43 [95% CI 0.29–0.62], p < 0.001) and severe COVID-19 subgroup (RR 0.48 [95% CI 0.32–0.72], p < 0.001). CONCLUSIONS: Ivermectin was associated with decreased mortality in COVID-19 with a low certainty of evidence. Further adequately powered double-blinded placebo-controlled RCTs are required for definite conclusion. Most medications that is touted for COVID-19 failed to demonstrate benefit in randomized controlled trials (RCTs). In an effort to find treatment, there is a mounting interest on repurposing the available antiviral and antiparasitic medications to treat COVID-19. One of the most promising drugs is ivermectin, a macrocyclic lactone antiparasitic drug, well known for its broad spectrum antiparasitic activity, and has excellent safety profile. [7, 8] Highly versatile, ivermectin shows activity beyond its antiparasitic properties, including antimicrobial, antiviral, and anticancer. [9] [10] [11] [12] [13] [14] Recent studies have shown its antiviral activity against several A comprehensive systematic literature search was performed using PubMed, Scopus, Embase, and Clinicaltrials.gov (Filter: Completed) using terms "(SARS-CoV-2 OR COVID-19 OR 2019-nCoV OR Coronavirus Disease 2019) AND (ivermectin)" from the inception of databases up until 9 April 2021. Two independent authors screened through the title/abstracts and potentially eligible articles were assessed based on the inclusion and exclusion criteria. Discrepancies during this process were resolved by discussion. Studies that met all of the following criteria were included: 1) randomized controlled trials (RCTs) comparing ivermectin versus control in patients with COVID-19 and 2) mortality. Studies that met one of the following criteria were excluded: 1) conference papers/abstractsonly publication, 2) non-research letters, 3) reviews, and 4) editorial/commentaries. We did not impose language restrictions. Data extraction was performed by two independent authors. The data of interest for this systematic review were the first author, study design, ivermectin dose, sample size, percentage of severe COVID-19, age, sex, diabetes, hypertension, coronary artery disease, and mortality. Discrepancies were resolved by discussion. To assess the risk of bias, two independent authors used the Cochrane Risk of Bias (RoB) Assessment for RCTs. Discrepancies were resolved by discussion. Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework was used to determine the certainty of evidence. The intervention group was ivermectin with or without standard of care. The control group was placebo or standard of care defined by each trial. The primary outcome was mortality, defined as clinically validated non-survivor/death. The pooled effect estimate was reported as risk ratio (RR). To calculate the pooled RRs for the primary outcome, we performed Der-Simonian Laird random-effects meta-analysis, regardless of heterogeneity. The p-values in this study was twotailed and a value of ≤ 0.05 were considered as statistically significant. Cochran's Q test and I 2 statistics were used to evaluate heterogeneity, I 2 values above 50% or/and p-value below 0.10 indicates significant heterogeneity. Funnel-plot analysis and Egger's test were used to assess publication bias and potential for small-study effects. STATA version 16.0 was used to perform the statistical analysis. Meta-regression analysis was performed for the association between ivermectin and mortality reduction using patients' characteristics as covariates. Sensitivity analysis using Mantel-Haenzsel fixed-effect model was performed. Baseline Characteristics There were 9 RCTs comprising of 1,788 patients included in this systematic review and metaanalysis [ Figure 1 ]. [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] Baseline characteristics of the included studies can be seen in Table 1 . Ivermectin was associated with decreased mortality (RR 0. This meta-analysis showed that ivermectin reduce mortality in patients with COVID-19 with a low certainty of evidence. Meta-regression indicates that the benefit of ivermectin use was smaller in patients with hypertension. Hypertension is associated with worse prognosis in patients with COVID-19, and drugs such as angiotensin receptor blockers might affect their prognosis. [29, 30] The included studies did not report the stage of hypertension, controlled/uncontrolled, and medications used in hypertensive patients; which may confound the association. The underlying mechanism for this observation is unclear and requires further investigation. However, this observation might be due to 100% severe COVID-19 in two studies which enroll high percentage of hypertension (Galan et al. [24] and NCT04646109 [26] ), also these studies did not clearly report the presence of coronary artery disease or heart failure, which are important complications of hypertension. Thus, the finding might also be a coincidence or an indicator of other end organ complications. Interestingly, diabetes does not significantly affect ivermectin's benefit. Some antidiabetic J o u r n a l P r e -p r o o f drugs have been shown to lower mortality in COVID-19 and glucose control seemed to be an important component in these patients. [31] [32] [33] [34] These factors were vaguely reported by the included studies and may affect the analysis. Ivermectin is a macrocyclic lactone antiparasitic drug which is well known for its broad spectrum antiparasitic activity, high efficacy, and excellent safety profile. [7, 8] Known for its versatility, ivermectin shows wide array of antimicrobial, antiviral, and anticancer activities. [9] [10] [11] [12] [13] [14] Recent studies have shown that ivermectin has antiviral activity against several RNA viruses, which might be useful in combating SARS-CoV2. [15] [16] [17] [18] Ivermectin is a mixture of both equipotent 22,23-dihydroavermecton B1a (80%) and 22,23dihydroavermectin B1b (20%). [7, 8] Ivermectin's potential antiviral activity against several RNA viruses including, zika virus, influenzae A virus, human immunodeficiency virus (HIV) and dengue virus has been demonstrated. [18, 35, 36] One of the most important antiviral mechanism is the inhibition of importin α/β1 heterodimer, which is essential for nuclear trafficking viral protein, thus important for viral replication. [17, 35, 37] Another possible mechanism that had been discovered in the past, but was not fully explained, is the role of ivermectin as an ionophore agent. [11] Ionophores are molecules which have both hydrophilic pockets that serve as an ion binding site, covered by hydrophobic on the external surface. These properties allow ionophore to cross across cell membrane, affecting hydro-electrolyte balance. The two structures that form ivermectin, reacting with each other in a "head-tail" fashion. This configuration is possibly mediated by plasma transport proteins, such as albumin. [38] The conformation eventually would lead to osmotic lysis and help neutralizing the virus at an early stage of infection. [39] This mechanism is proposed to be effective in viruses J o u r n a l P r e -p r o o f without a protein capsid, which will resist osmotic lysis. [7] SARS-CoV2 is present with only a phospholipid envelope with few proteins inserted within. [40] Ivermectin also demonstrates in vivo and in vitro anti-inflammatory activities, through reducing the production of inflammatory cytokines such as TNF-alpha, interleukin-1 (IL-1) and interleukin-6 (IL-6). [41] In mice, administration of ivermectin suppresses mucous hypersecretion and the production of inflammatory cytokines in the sample that was taken from bronchoalveolar lavage. [42] Ivermectin also appears to inhibit SARS-CoV2 replication in vitro and show a ~5000 fold reduction in viral RNA at 48 hours. [43] Although the exact mechanism is not fully elucidated, it is proposed that multiple mechanisms such as inhibition of importin α/β1 heterodimer and the role of ivermectin as ionophore might contribute to its broad-spectrum antiviral activity. [43, 44] Despite promising results and satisfactory safety profile, the use of ivermectin is limited to its pharmacokinetic problems such as low solubility and high cytotoxicity. [45] Therefore, more controlled studies are needed to determine the benefit of ivermectin in COVID-19. Most of the included studies were preprints, which is not yet peer-reviewed, and presented as a potential source of bias; this is the most important limitation of this meta-analysis. It is known that studies with positive results are likely to be published or reported, and the accuracy of meta-analysis highly depends on the source material. The presence of publication bias is also supported by the funnel-plot analysis and Egger's test. Most studies individually reported a pvalue of >0.05, this might be caused by inadequately powered trial (low incidence of mortality J o u r n a l P r e -p r o o f and inadequate sample size). However, it should be noted that the only study reporting significant effect was at high risk of bias (too many uncertainties upon RoB assessment) [23] . The dose and length of ivermectin administration varied across the studies. Most of the studies also did not report important parameters such as chronic kidney disease, heart disease, medications for chronic diseases [46] , and laboratory parameters such as d-dimer and creactive proteins which may affect prognosis. Thus adequately powered double-blinded placebo-controlled RCTs with similar baseline characteristics and dosing among the intervention and control groups are required before a definite conclusion can be made. Ivermectin was associated with decreased mortality in patients with COVID-19 with a low certainty of evidence. Further double-blinded placebo-controlled RCTs with large samples are required for definite conclusion. In the future, if the pre-prints publication is published with the similar result to the current analyses, the certainty of evidence will increase. C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis Elevated interleukin levels are associated with higher severity and mortality in COVID 19 -A systematic review, meta-analysis, and meta-regression Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action The pharmacokinetics and interactions of ivermectin in humans -A mini-review Anthelmintic avermectins kill mycobacterium tuberculosis, including multidrug-resistant clinical strains The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug Anti-parasitic Drug Ivermectin Exhibits Potent Anticancer Activity against Gemcitabine-resistant Cholangiocarcinoma in Vitro Ivermectin exhibits potent anti-mitotic activity Topical ivermectin improves allergic skin inflammation Nuclear trafficking of proteins from RNA viruses: Potential target for antivirals? Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer Influenza A viruses escape from MxA restriction at the expense of efficient nuclear vRNP import Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019: The Ivermectin in COVID Nineteen Study Ivermectin as a potential treatment for mild to moderate COVID-19 -A double blind randomized placebocontrolled trial Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin in hospitalized patients with severe manifestations of SARS-CoV-2 infection Efficacy and safety of Ivermectin and Hydroxychloroquine in patients with severe COVID-19. A randomized controlled trial Corresponding Authors Ivermectin for Severe COVID-19 Management -NCT04646109-ClinicalTrials Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection -NCT04523831 -ClinicalTrials Effect of Ivermectin on Time to Resolution of Symptoms among Adults with Mild COVID-19: A Randomized Clinical Trial The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: A systematic review, meta-analysis and meta-regression Prognostic value of fasting hyperglycemia in patients with COVID-19 -Diagnostic test accuracy meta-analysis The Effect of Metformin Consumption on Mortality in Hospitalized COVID-19 patients: a systematic review and meta-analysis Dipeptidyl peptidase-4 (DPP-4) inhibitor and mortality in coronavirus disease 2019 (COVID-19) -A systematic review, meta-analysis, and meta-regression Diabetes and COVID-19: The Past, The Present, and The Future Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection Ivermectin: Enigmatic multifaceted "wonder" drug continues to surprise and exceed expectations Ivermectin binds avidly to plasma proteins Osmotic shock and the strength of viral capsids A potential role for integrins in host cell entry by SARS-CoV-2 Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice Anti-inflammatory effects of ivermectin in mouse model of allergic asthma The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro Antiviral and Anti-Inflammatory Properties of Ivermectin and Its Potential Use in COVID-19 Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19 Active prescription of low-dose aspirin during or prior to hospitalization and mortality in COVID-19: A systematic review and meta-analysis of adjusted effect estimates J o u r n a l P r e -p r o o f